Total trials
53
Active
17
Phase 3
3
Total enrollment
51,197
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Elacestrant | — | — | — | — | — | 1 | |
| Standard of care | — | — | — | — | — | 1 | |
| Zanubrutinib | — | — | — | — | — | 1 | |
| Obinutuzumab | — | — | — | — | — | 1 | |
| Vorasidenib | — | — | — | — | — | 1 | |
| Selinexor | — | — | — | — | — | 1 |
Next readouts
- 2026-10-30
- 2028-06
- 2028-08
- 2031-11
Top conditions
- Multiple Myeloma7
- Breast Cancer7
- Renal Cell Carcinoma3
- Chronic Lymphocytic Leukemia (CLL)2
- HER2-positive Breast Cancer2
- Metastatic Breast Cancer2
- Cholangiocarcinoma2
- Hormone Receptor Positive Tumor2
Frequently asked questions about iOMEDICO AG
- How many clinical trials does iOMEDICO AG have on ClinicalTrials.gov?
- iOMEDICO AG is listed as the lead sponsor on 53 clinical trials in ClinicalTrials.gov, 17 of which are currently active (recruiting, enrolling, or ongoing).
- How many of iOMEDICO AG's trials are in Phase 3?
- 3 of iOMEDICO AG's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does iOMEDICO AG focus on?
- iOMEDICO AG's most-studied conditions on ClinicalTrials.gov are Multiple Myeloma, Breast Cancer, Renal Cell Carcinoma, Chronic Lymphocytic Leukemia (CLL), HER2-positive Breast Cancer.
- When are iOMEDICO AG's next clinical trial readouts?
- iOMEDICO AG has 4 upcoming primary-completion readouts tracked here; the soonest is “Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma”, expected around 2026-10-30.